miR-17–92 cluster is connected with disease progression and oxaliplatin/capecitabine chemotherapy efficacy in advanced gastric cancer patients

Abstract

This study aimed to determine the role of plasma miR-17-92 cluster level in predicting chemoresistance in patients with gastric cancer (GC) undergoing oxaliplatin/capecitabine (XELOX) chemotherapy.Patients recently diagnosed with advanced GC were chosen as participants based on the inclusion criteria. The plasma levels of miR-17-5p, miR-18a, miR-19a/b, miR-20a, and miR-92-1 (miR-17-92 cluster) were determined through quantitative RT-PCR of blood samples from GC patients and healthy volunteers. All the patients received XELOX chemotherapy, and the effectiveness of the chemotherapy was evaluated.The miR-17-92 plasma level was increased in advanced GC patients and decreased after XELOX chemotherapy. Moreover, the miR-17-92 cluster level was associated with chemotherapy response but not with chemotherapy-related toxicity. The miR-17-92 cluster plasma level was decreased in chemosensitive patients, but not in chemoresistant patients, after chemotherapy. The sensitivity and specificity of the combined detection of the miR-17-92 cluster in patients with advanced GC were 100% each.The results suggest that the miR-17-92 plasma level is associated with the progression of advanced GC and effectiveness of XELOX chemotherapy.

Identification of biomarkers predicting the chemotherapeutic outcomes of capecitabine and oxaliplatin in patients with gastric cancer

“…In addition, a variety of noncoding RNAs are associated with capecitabine and oxaliplatin resistance in GC cells (8,15).…”

“…Sensitization strategies for effective GC CapeOX regimens remain to be found. Studies on genome-wide research have revealed the diversity and the complex genetic alterations of patients with GC, which can explain the differing responses of different patients during chemotherapy (7,8). Currently, few biomarkers for the prediction of CapeOX chemotherapy have been validated for clinical use.…”

Noncoding RNAs in gastric cancer: implications for drug resistance

“…Significantly increased plasma miR-17-92 cluster levels has been found in advanced gastric cancer patients. Whereas, there was obvious decrease of these miRNAs in chemosensitive individuals after oxaliplatin/capecitabine (XELOX) chemotherapy, indicating they might be used as biomarkers of XELOX treatment [160].…”

Current Advancement of the miR-17-92 Cluster in Gastrointestinal Cancers

“…The miR-17-92 cluster not only participates in the progression of gastric cancer but also could be used to monitor therapeutic utility. Fan et al tested the expression of the miR-17-92 cluster in the plasma of gastric cancer patients undergoing traditional chemotherapy with oxaliplatin/capecitabine (XELOX) [72]. The results showed that the miR-17-92 cluster was expressed at higher levels in advanced gastric cancer and was downregulated after chemotherapy.…”